Future Directions in Research, Treatment and Prevention of HPV-Related Squamous Cell Carcinoma of the Head and Neck

Head and Neck Pathology

Volumn 6, Issue SUPPL. 1, 2012, Pages 121-128

  Psyrri, Amanda ^a,b   Sasaki, Clarence ^b   Vassilakopoulou, Maria ^b   Dimitriadis, George ^a   Rampias, Theodoros ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

De intensification; HPV; OSCC; Targeted therapies; Vaccines

Indexed keywords

CHEMORADIOTHERAPY; HEAD AND NECK TUMOR; HUMAN; PAPILLOMAVIRUS INFECTION; REVIEW; SQUAMOUS CELL CARCINOMA; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; HEAD AND NECK NEOPLASMS; HUMANS; PAPILLOMAVIRUS INFECTIONS;

EID: 84864130994     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-012-0361-8     Document Type: Review

References (33)

1. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Nat Cancer Inst. 2000; 92(9): 709-20.
2. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol Off J Am Soc Clin Oncol. 2006; 24(5): 736-47.
3. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol Off J Am Soc Clin Oncol. 2011; 29(32): 4294-301.
4. Goodwin EC, Yang E, Lee CJ, et al. Rapid induction of senescence in human cervical carcinoma cells. Proc Nat Acad Sci USA. 2000; 97(20): 10978-83.
5. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004; 78(21): 11451-60.
6. Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Nat Acad Sci USA. 2000; 97(23): 12513-8.
7. Tan TM, Ting RC. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res. 1995; 55(20): 4599-605.
8. Rampias T, Sasaki C, Weinberger P, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Nat Cancer Inst. 2009; 101(6): 412-23.
9. Mellin H, Dahlgren L, Munck-Wikland E, et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer. 2002; 102(2): 152-8.
10. van Tine BA, Dao LD, Wu SY, et al. Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning. Proc Nat Acad Sci USA. 2004; 101(12): 4030-5.
11. Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Nat Acad Sci USA. 2006; 103(38): 14152-7.
12. Rampias T, Boutati E, Pectasides E, et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res MCR. 2010; 8(3): 433-43.
13. Hayward SD, Liu J, Fujimuro M. Notch and Wnt signaling: mimicry and manipulation by gamma herpesviruses. Sci STKE 2006; 2006(335): re4.
14. Tumban E, Peabody J, Peabody DS, et al. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS ONE. 2011; 6(8): e23310.
15. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011; 365(17): 1576-85.
16. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6(5): 271-8.
17. Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs. 2010; 70(9): 1079-98.
18. Lu B, Kumar A, Castellsague X, et al. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011; 11: 13.
19. D'Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Preventive Med. 2011; 53(Suppl 1): S5-11.
20. Maeda H, Kubo K, Sugita Y, et al. DNA vaccine against hamster oral papillomavirus-associated oral cancer. J Int Med Res. 2005; 33(6): 647-53.
21. Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccine. 2011; 7(2): 161-9.
22. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007; 25(26): 4931-9.
23. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009; 361(19): 1838-47.
24. Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS ONE. 2011; 6(5): e19252.
25. Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol Off J Am Soc Clin Oncol. 2009; 27(35): 5911-8.
26. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Nat Cancer Inst. 2008; 100(4): 261-9.
27. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02. 02 phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010; 28(27): 4142-8.
28. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1): 24-35.
29. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol Off J Eur Soc Med Oncol (ESMO). 2011; 22(5): 1071-7.
30. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6): 567-78.
31. Bonner JA, Ang K. More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med. 2007; 357(18): 1872-3.
32. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11(1): 21-8.
33. Koutcher L, Sherman E, Fury M, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Rad Oncol Biol Phys. 2011; 81(4): 915-22.